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Abstract
Cigarette smoke (CS)-induced emphysema is an important contributor to chronic ob-
structive pulmonary disease (COPD). We have shown the efficacy of azithromycin 
in reducing airway inflammation in COPD and in reducing exacerbations in severe 
asthma; however, the effects of long-term azithromycin on emphysema development 
have not been shown. We employed live animal imaging to monitor emphysema-
like development and ®the effects of interventional azithromycin treatment in CS-
exposed mice. BALB/c mice (female, 10 weeks; n = 10) were exposed to CS for 1 hr 
twice daily, 5 days/week, and for 12 weeks (CS). Half were cotreated with low-dose 
azithromycin during weeks 7–12 (CS + Azi; 0.2 mg kg−1 day−1). Microcomputed 
tomography (CT) and magnetic resonance imaging (MRI) scans were acquired longi-
tudinally. Histological examinations were performed post mortem (mean linear inter-
cept (Lm) and leukocyte infiltration). CS increased median Lm (CS: 42.45 µm versus 
control: 34.7  µm; p  =  .0317), this was recovered in CS  +  Azi mice (33.03  µm). 
Average CT values were reduced in CS mice (CS: −399.5 Hounsfield units (HU) 
versus control: −384.9 HU; p  =  .0286) but not in CS  +  Azi mice (−377.3 HU). 
CT values negatively correlated with Lm (r = −.7972; p = .0029) and T2-weighted 
MRI (r  =  −.6434; p  =  .0278). MRI also showed significant CS-induced inflam-
matory changes that were attenuated by azithromycin in the lungs, and positively 
correlated with Lm (r = .7622; p = .0055) and inflammatory foci counts (r = .6503; 
p =  .0257). Monitoring of emphysema development is possible via micro-CT and 
MRI. Interventional azithromycin treatment in CS-exposed mice attenuated the de-
velopment of pulmonary emphysema-like changes.
K E Y W O R D S
chronic obstructive pulmonary disease, COPD, emphysema, in vivo imaging, magnetic resonance 
imaging, micro-CT, mouse model
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1 |  INTRODUCTION
Emphysema, alongside chronic bronchitis, is the most com-
mon condition in chronic obstructive pulmonary disease 
(COPD), for which cigarette smoke (CS) is the most com-
mon causative factor. The World Health Organization expects 
COPD to become the third leading cause of death worldwide 
by 2030 (Alwan, (2010); Quaderi & Hurst, 2018). As COPD is 
incurable, and current therapies primarily target only disease 
symptoms, there is an urgent need for novel treatment strat-
egies. In contrast to healthy airways, COPD patients exhibit 
chronic lung inflammation and loss of structural integrity in 
both the large and small airways (Jeffery, 2001). Emphysema 
is characteristic of CS-induced COPD, and involves the de-
struction of lung parenchyma and permanent enlargement of 
the alveolar spaces distal to the terminal bronchioles (Jeffery, 
2001; Snider, Kleinerman, Thurlbeck, & Bengali, 1985).
Azithromycin is a macrolide antibiotic derived from 
erythromycin that is known to be effective against many 
Gram-negative bacteria, including some of clinical relevance 
in COPD such as (non-typeable) Haemophilus influenzae 
(Hodge et al., 2017; Peters, Friedel, & McTavish, 1992). In 
addition to its antimicrobial function, it has been shown to 
have anti-inflammatory activity which may contribute to its 
observed therapeutic effects in asthma and COPD patients 
(Segal et al., 2017). We have previously shown that low-dose 
azithromycin treatment in COPD patients improves macro-
phage clearance of apoptotic cells and bacteria, and reduces 
airway inflammation (Albert et al., 2011; Hodge et al., 2008; 
Hodge & Reynolds, 2012; Pomares et al., 2011). Others 
have reported that long-term azithromycin treatment also 
decreased COPD exacerbations and improved quality of life 
(Albert et al., (2011); Pomares et al., 2011). We have further 
shown its efficacy in reducing exacerbations in severe asth-
matic patients who can also suffer from chronic lung inflam-
mation (Gibson et al., 2017).
There have been limited studies of the effects of mac-
rolide antibiotics in emphysematous animal models. One 
study reported the success of clarithromycin in preventing 
CS-induced emphysema-like changes in a mouse model 
(Nakanishi et al., 2009), while prior work in a rat model of 
CS-induced COPD showed that daily intragastric administra-
tion of azithromycin (50 mg/kg) attenuated emphysema-like 
changes and lung function (FEV1) loss, and reduced inflam-
matory cell numbers (Wan et al., 2015).
However, no study has investigated whether a macro-
lide can attenuate development of emphysema-like changes 
when administered at a low dosage following CS-induced 
development of an inflammatory, yet pre-emphysematous 
lung environment. This model is representative of a treat-
ment that prevents emphysema development in a smoker ex-
periencing minor lung distress. Therefore, in this study, we 
utilized live animal imaging to monitor the inflammatory 
lung environment and emphysema-like changes develop-
ment in CS-exposed mice treated with interventional inhaled 
azithromycin.
2 |  METHODS
2.1 | Cigarette smoke exposure and 
Azithromycin treatment
The protocol was adapted from our previous publications 
(Beckett et al., 2013; Hodge et al., 2010, 2011; Mukaro 
et al., 2013). Female BALB/c mice (10 weeks old; CS and 
CS + Azi: n = 5 mice/group) were exposed to mainstream 
CS from nine research cigarettes (1R6F reference cigarette, 
University of Kentucky, KY, USA) for 1  hr, twice daily, 
5 days/week, for 12 weeks. The protocol utilized the inEx-
pose system and whole-body chambers (Scireq Inc, QC, 
Canada), control mice (n = 5) were exposed to fresh air in an 
adjacent inExpose chamber. inExpose puff profile was con-
figured to deliver 2 L/min fresh air, with an ISO standard CS 
puff once every 30 s. Cigarettes were burnt to 3 mm from the 
tipping paper. During weeks 7–12, the CS + Azi cohort were 
exposed to 0.2 mg kg day−1 of azithromycin via nebulization 
[azithromycin (Sigma Aldrich, MO, USA) dissolved in pH 
6.0 PBS] into the inExpose whole-body chamber once per 
day following their second CS session.
Animals were housed within a specific pathogen-free bar-
rier facility, in separate cages for each cohort, with a tem-
perature range 18–24°C, 12:12 hr light-dark cycle, and few 
regular chow ad-libitum. The experiments were approved 
by SAHMRI Animal Ethics Committee (SAM361) and con-
ducted within the National Health and Medical Research 
Council of Australia guidelines on animal experimentation.
2.2 | Histological processing
Lung tissues were perfused with 10% formalin solution 
(Chem-Supply, SA, Australia), fixed overnight then embed-
ded. Five µm sections were stained with H&E, then imaged 
at 20× objective resolution using a NanoZoomer 2.0-HT 
(Hamamatsu Photonics, Japan), and viewed using NDP.view 
2 software (Hamamatsu) for further analysis.
2.3 | Calculation of mean linear intercept
Mean linear intercept (Lm) values advised alveolar size and 
the extent of emphysematous changes (Aoshiba, Yokohori, 
& Nagai, 2003; Nadziejko, Fang, Bravo, & Gordon, 2007). 
To calculate Lm, 5 nonoverlapping regions/mouse were sys-
tematically acquired (20× objective resolution) from each 
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of three sections approximately 120 µm apart. These images 
were analyzed via Fiji (Schindelin et al., 2012) using an in-
house script. Briefly, a) the image size was calibrated; b) an 
overlay with parallel lines was added, and a selection created 
from the tissue components which were subtracted from the 
grid; c) the remaining lines (minimum length 10 µm) were 
automatically measured, and the average length returned, that 
is, Lm. This was repeated with both horizontal and vertical 
lines to avoid rotation bias. Only regions without bronchi-
oles, large blood vessels (>50 µm), and other nonairway sec-
tions were selected.
2.4 | Microcomputed tomography
Micro-CT images were acquired via the Skyscan 1,176 
(Bruker Physik GmbH, Germany) at weeks 0, 6, 8, 10, and 
12 using a 55 kV source voltage, 455 µA source current, 0.7° 
rotation step, 200 ms exposure, and 18 µm pixel size; physi-
ological monitoring mode was synchronized to chest move-
ment. Ten-minute average scan times resulted in an average 
whole-body exposure of 155 mGy/scan. Mice were scanned 
supine and anesthetized with an isoflurane/oxygen mixture. 
Hounsfield units (HU) were calibrated prior to each imaging 
session by scanning a 50-mL tube of distilled water.
Images were reconstructed between HU values of −1000 
and 1,000 using NRecon (Bruker) with smoothing of 6, 
ring-artifact reduction of 5, and beam-hardening correction 
of 20%. Using DataViewer (Bruker), datasets were realigned, 
and the lung volume of interest dorsal on the sagittal plane to 
between the third and fourth sternebrae and between the T9 
and T10 thoracic vertebrae was selected [to highlight emphy-
sematous changes (Snider et al., 1985), and for its approxi-
mation to previous segmentation strategies in human studies 
(Hoesein et al., 2012; Lee, Kim, Kim, Ahn, & Kim, 2018)]. 
Images were analyzed in CTan (Bruker), and average lung 
HU values recorded.
2.5 | Magnetic resonance imaging
Two T1-weighted gradient echoes were acquired: (TR/
TE = 300.9/6.21 ms; 1 NEX; vow = 80 mm2; slice thick-
ness = 2 mm; <1 min), and a longer scan with higher resolu-
tion (TR/TE = 382.9/6.21 ms; 4 NEX; vow = 80 mm2; slice 
thickness  =  2  mm; 6.5  min). Then, a T2-weighted RARE 
spin-echo sequence was acquired (TR/TE = 4,314.3/84 ms; 1 
NEX; rare factor = 8; vow = 80 mm2; slice thickness = 2 mm; 
<2 min). ITK-SNAP software (Yushkevich et al., 2006) was 
used for consequent segmentation and analysis of the scans. 
T2-intensity ratios were calculated by dividing mean image 
intensity of the lungs (and kidneys) by the mean intensity of 
arm muscle in the same slices to normalize values.
2.6 | Enumeration of leukocyte 
infiltration foci
To determine leukocyte infiltration, focal clusters of 
>20 infiltrating leukocytes were counted in NDP.view 2 
(Hamamatsu). Entire lung sections were scored, and total 
area measured (3 sections/mouse; approximately 120  µm 
apart). Foci per 20 mm2 were calculated.
2.7 | Statistical analyses
Kruskal–Wallis and Mann–Whitney U-tests, or Wilcoxon 
signed rank tests were applied as appropriate. Spearman's 
rank-order correlation was used to assess association be-
tween variables. Analyses were performed using GraphPad 
Prism 7 (GraphPad Software, CA, USA). Data are presented 
as median and range, unless otherwise specified. p < .05 sta-
tistically significant.
3 |  RESULTS
3.1 | Animal welfare
No signs of stress were evident during handling or the CS ex-
posure protocol in BALB/c mice. During the first 2 weeks, the 
majority of mice became visibly drowsy by the third or fourth 
cigarette, however, this effect lessened over time, as the mice 
became more accustomed to CS exposure. CS-exposed mice 
were also more lethargic when returned to their cages, but ap-
peared to recover fully within 1–2 hr. By approximately week 
4 of exposure, mice were eager to enter the Scireq apparatus, 
presumably due to nicotine addiction; this was especially evi-
dent on Mondays following 2 days without cigarettes.
CS-exposed mice failed to gain weight until week 7 (con-
trary to controls), although weight loss never exceeded 6% 
(Figure 1a); this is similar to a previous CS exposure study 
in BALB/c mice (Beckett et al., 2013). It should be noted 
that the CS-exposed BALB/c mice used in this study became 
visibly stained by the CS, and therefore during grooming it is 
possible they were further exposed to tar and nicotine.
3.2 | Histological assessment of alveolar 
destruction
To examine the therapeutic potential of inhaled azithromycin 
treatment in reducing CS-related emphysematous changes in 
the lungs, BALB/c mice were exposed to CS for 6 weeks, then 
CS ± azithromycin for an additional 6 weeks. Lm was signif-
icantly greater in CS mice compared with controls [20.09% 
increase; CS: 42.45µm (38.95 – 53.1), control: 34.7 µm (29 
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– 40.22); p = .0317] (Figure 2d). CS + Azi mice showed no 
difference in Lm compared with controls [33.03 µm (31.72 – 
34.2)] (Figure 2d).
3.3 | Micro-CT analysis of the lungs
Average CT values (mean HU) from micro-CT scans, re-
stricted to the lower lung, acquired at weeks 0, 6, 8, 10, and 
12 were analyzed. Kruskal–Wallis analysis of percentage 
changes revealed no significant intercohort differences at the 
time points examined (Figure 1c). Longitudinal tracking of 
absolute average HU in the lower lungs suggested significant 
decreases in density over the first 6  weeks in CS-exposed 
mice [−399.1 HU (−412.4 – −336.6) in week 6 versus −357 
HU (−370.2 – −301.9) in week 0; p = .0022]. Control mice 
also showed a decrease [−373.9 HU (−387 – −366.3) in 
week 6; p  =  .0132] (Figure  1c-d). However, there was no 
significant differences between control and CS-exposed co-
horts at this time (p = .1535). Treatment of both CS-exposed 
groups was identical during this period.
Significantly decreased average HU values in the lower 
lungs were observed in CS mice at week 12 [−399.5 HU 
(−408.2 – −394.5)] compared with both control mice 
[−384.9 HU (−390.1 – −373)] and CS + Azi mice [−377.3 
HU (−384.2 – −370.2)] (Figure 1e; p = .0286). CS + Azi 
mice presented with average HU values similar to controls, 
and significantly greater than CS mice (p = .0286). Week 
12 average HU values also showed significant negative 
correlation with Lm (Spearman r  =  −.7972; p  =  .0029) 
(Figure 1f).
3.4 | MRI Analysis of the lungs
MRI examination of lung inflammation revealed a 27.28% 
increase in T2-weighted signal intensity ratio in CS mice 
(p = .0286), while CS + Azi mice exhibited nonsignificant 
differences from controls (Figure 3c). Similar analysis of the 
kidneys was also performed to detect inflammatory changes 
elsewhere in the body; T2 signal intensity was increased by 
29.3% in CS mice (p = .0286) (Figure 3b). These MRI val-
ues negatively correlated with average HU values (Spearman 
r  =  −.6434; p  =  .0278) (Figure  3d), while showing sig-
nificant positive correlation with Lm (Spearman r = .7622; 
p = .0055) (Figure 3e).
F I G U R E  1  Emphysematous changes 
in CS-exposed mice via micro-CT analysis 
of the lower lung are attenuated by 
azithromycin. (a) Percentage changes in 
mouse weight over time. (b) Representative 
micro-CT image slice of a mouse lung prior 
to processing (left) and postthresholding 
(right). (c) Time course of average 
Hounsfield unit (HU) values of the lower 
lungs (mean ± SD). (d) Average HU values 
at week 6. (e) Average HU values at week 
12 prior to postmortem. (f) Correlation 
of week 12 average HU values with Lm. 
Data presented as median ± range (unless 
otherwise stated). * represents significance 
between cohorts, p < .05. Dotted lines show 
the 95% confidence interval
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3.5 | Perivascular and periepithelial 
leukocyte infiltration
Leukocyte infiltration foci (Figure  4a-b) were in-
creased 9.98-fold in CS mice [10.98 foci/20  mm2 
(8.079–12.180) versus 1.1 foci/20  mm2 (0.277–1.927) in 
controls; p = .0159] and 4.7-fold in CS + Azi mice [5.147 
foci/20 mm2 (4.460 – 7.014); p =  .0159] compared with 
controls (Figure 4c). CS + Azi mice showed significantly 
fewer infiltration foci than CS mice (2.13-fold fewer; 
p  =  .0079). Numbers of leukocyte infiltration foci pre-
sent in the lungs showed significant positive correlation 
F I G U R E  2  Assessment of 
emphysema-like changes in the lungs. (a–c) 
Representative H&E-stained lung sections 
at 12 weeks. (a) control, (b) CS-exposed 
(CS), and (c) CS-exposed + azithromycin 
treatment (CS + Azi). Scale bar is 250 µm. 
(d) Mean linear intercept (Lm) values were 
taken as a measure of alveolar size and 
emphysematous changes. Data represent 
the average Lm based on the measurements 
taken from 3 lung sections per mouse; 
median ± range. n = 4–5 mice/group. * 
represents significance between cohorts, 
p < .05; ** indicates p < .01
a b
c d
F I G U R E  3  Inflammation in the 
lungs and kidneys of CS-exposed mice 
is attenuated by azithromycin. (a) 
Representative coronal, T2-weighted MR 
images of live mice. (b and c) Comparison 
of T2 intensity in the lungs and kidneys. (d) 
Correlation of T2-weighted MRI intensity 
values of the lung and average CT value 
(HU). (e) Correlation of T2-weighted 
MRI intensity values of the lung and Lm. 
Data presented as median ± range. Dotted 
lines show the 95% confidence interval. * 
represents significance between cohorts, 
p < .05. Dotted lines show the 95% 
confidence interval. n = 4 mice/group
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with MRI T2 signal intensity ratio (Spearman r =  .6503; 
p = .0257) (Figure 4d).
4 |  DISCUSSION
Emphysema and increased inflammation are two components 
characteristic of the COPD phenotype. Emphysema severity 
is highly variable among COPD patients (even those at the 
same stage of disease progression) and increased severity is 
associated with poorer quality of life (Makita et al., 2007). 
We and others have previously highlighted the potential of 
macrolide antibiotics (viz., azithromycin) in COPD for re-
ducing inflammation (Zarogoulidis et al., 2012) and pulmo-
nary exacerbations (Albert et al., 2011; Pomares et al., 2011), 
improving bacterial clearance (Hodge et al., 2008; Hodge & 
Reynolds, 2012), and increasing the phagocytosis of apop-
totic airway cells, that is, efferocytosis (Hodge et al., 2006). 
The macrolide antibiotic clarithromycin has also been shown 
to prevent CS-induced emphysema-like changes in mice via 
oral administration at doses ranging from 25 to 100 mg/kg 
twice daily (Nakanishi et al., 2009).
While these represent promising findings, there are 
concerns regarding the potential for selection of resistant 
bacteria following prolonged macrolide use at antibiotic con-
centrations (Taylor et al., 2019; Zarogoulidis et al., 2012). 
Our previous study investigating long-term, low-dose azith-
romycin use in asthma patients (500 mg tablets three times 
per week for 48  weeks) found a nonsignificant increase in 
sputum isolation of azithromycin-resistant organisms com-
pared with placebo patients [19 (50%) versus 12 (29%) of 42 
organisms; p =  .062] (Gibson et al., 2017). Another recent 
study using the same treatment in asthma patients reported 
a significant increase in azithromycin-resistant bacterial iso-
lates and overall expression of antibiotic resistance genes 
in the lungs, however, it noted that this was not associated 
with increased isolation of pathogenic species (Taylor et al., 
2019). In an attempt to minimize the selection pressure while 
retaining its immunomodulatory effects, this study treated 
CS-exposed mice daily with low-dose azithromycin (0.2mg/
kg) via inhalation of nebulized solution to target the lungs (as 
opposed to oral administration). This low dosage was chosen 
for its equivalence to our previous work both in vitro (Hodge 
et al., 2006, 2017) and in a human phase II study in COPD, 
where low-dose azithromycin [250 mg orally for 5 days, then 
twice weekly (total of 12 weeks)] demonstrated anti-inflam-
matory effects and improved alveolar macrophage phagocytic 
and efferocytic function(Hodge et al., 2008, 2017; Hodge & 
Reynolds, 2012).
Induction of emphysema-like changes was confirmed in 
our CS mice through Lm measurements. The observed in-
crease of approximately 20% is comparable with prior work in 
F I G U R E  4  CS-exposed mice showed 
increased leukocyte infiltration into lung 
tissue that was attenuated by azithromycin. 
(a and b) H&E-stained lung sections from 
CS-exposed mice showing examples of 
leukocyte foci (white arrows) (a) near 
blood vessels (BV) and (b) airway epithelia 
(Epi). (c) Fold change in the number of 
leukocyte foci in the lungs. (d) Correlation 
between T2-weight MRI intensity values and 
leukocyte foci in the lung. Data presented 
as median ± range. Dotted lines show 
the 95% confidence interval. * represents 
significance between cohorts, p < .05; ** 
indicates p < .01. Dotted lines show the 95% 
confidence interval. n = 4–5 mice/group
a b
dc
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BALB/c and C57BL/6 mice, and reported to be indicative of 
emphysema in these animals (Beckett et al., 2013; Nadziejko 
et al., 2007; Nakanishi et al., 2009). Nose-only exposure of 
BALB/c mice to CS has been shown previously to induce 
hallmark features of human COPD including increased Lm 
after 8–12 weeks (Beckett et al., 2013). We therefore pres-
ent similar results at 12 weeks using less intense delivery via 
whole-body exposure chamber. We also found low-dose inter-
ventional azithromycin treatment attenuated Lm increase, that 
is, alveolar destruction, to control levels when administered 
during preemphysematous stages of development. Treatment 
with clarithromycin (50 mg/kg) from the commencement of 
CS exposure in C57BL/6 mice (Nakanishi et al., 2009), and 
also azithromycin (50  mg/kg) in Sprague–Dawley rats to a 
lesser degree (Wan et al., 2015), has been shown to achieve 
similar results. Importantly, we replicated these results using 
0.4% of the dose by direct administration to the lungs via inha-
lation of nebulized azithromycin solution, and achieved com-
parable results despite 6 weeks of prior CS exposure alone. 
Nebulizers are already used in the treatment of COPD and 
acute asthma attacks, and their efficacy and ease of use has 
been shown previously (Ferguson et al., 2019; Hossein et al., 
2016; Tashkin, 2016). Given that azithromycin is already ap-
proved for use in humans, and nebulizers are commonly used, 
this study warrants further investigation as a potential treat-
ment avenue for pre-COPD smokers, as there are currently 
no existing treatments for patients at the early stage of em-
physematous lung disease. It should, however, be noted that 
CS exposure in mice for 12 weeks cannot fully recapitulate 
the changes seen in humans, and our findings require confir-
mation in human studies of early-stage COPD development.
Time-course analysis of average CT values (HU) of the 
lower lung was statistically nonsignificant between cohorts 
until week 12; CS + Azi mice showed lung density recov-
ery to control levels by this time point. The significant de-
creases in lung density during the first 6 weeks were likely 
due to increases in mouse size and changing air space size 
(Kawakami, Paul, & Thurlbeck, 1984). In line with our find-
ings, a previous study only showed significant changes in CS 
mice, compared with controls, at the 12-week time point in 
C57BL/6 mice (Sasaki et al., 2015). The significant negative 
correlation between average HU values and Lm suggests that 
micro-CT analysis may offer an effective means of estimating 
emphysema-like development in live mice. Taking the CT 
and Lm results together, these findings point toward inter-
ventional azithromycin-related protection in CS + Azi mice. 
Further studies and optimization in different strains of mice 
used for modeling COPD are required to determine whether 
micro-CT analysis is feasible for the longitudinal tracking of 
emphysematous changes in the lungs.
The progressive airflow limitation observed in COPD 
patients results from a combination of emphysematous de-
struction of lung parenchyma and abnormal inflammatory 
responses; these changes are largely irreversible. Chronic 
inflammation in COPD patients persists despite cessation 
of smoking, and can increase further during exacerbations 
(Barnes, 2014, 2016). These inflammatory responses seen 
in COPD are characterized by increases in alveolar mac-
rophages, neutrophils, and T lymphocytes recruited to the 
lung parenchyma from the circulatory system (Barnes, 2016; 
Suzuki et al., 2017; Wang, Xu, Meng, Adcock, & Yao, 2018).
Mucus production or edema is usually seen in cases of 
experimental lung inflammation and lung injury, causing 
increased T2-weighted MRI signal intensity values to be 
observed (Beckmann et al., 2007). Therefore, the increased 
lung T2 signal intensity we report here in CS mice is likely 
the result of increased inflammation and fluid retention due 
to alveolar destruction and related elasticity loss (Beckmann 
et al., 2007), or potentially pulmonary infiltrates or thick-
ening of the bronchial walls (Wielpütz & Kauczor, 2012). 
Importantly, we demonstrate that low-dose azithromycin was 
able to reduce T2 signal intensity to near control levels fol-
lowing 6 weeks of treatment, despite the continuation of CS 
exposure throughout this period.
T2-weighted single-shot MRI with partial Fourier acqui-
sition (HASTE) has been used in humans to identify lung in-
filtrates, mucus accumulation, and inflammatory thickening 
of the bronchi in obstructive lung diseases (Ley-Zaporozhan, 
Puderbach, & Kauczor, 2008). Furthermore, a previous study 
in BALB/c mice investigating LPS-induced inflammation 
demonstrated positive correlation between MRI signal in-
tensity and histological analysis of lung injury (Conti et al., 
2010), while an elastase-induced model of emphysema in 
Brown Norway rats reported significant positive correlation 
between MRI and histological observations of perivascular 
edema and cellular infiltration (Quintana et al., 2006). This 
study supports these findings, showing a strong association 
between T2 signal intensity and Lm, as well as with increased 
immune cell infiltration.
Increased accumulation of leukocytes in the lung pa-
renchyma and abnormal inflammatory responses is cor-
related with airflow limitation and decreased lung function 
(O'Shaughnessy, Ansari, Barnes, & Jeffery, 1997; Saetta 
et al., 1998; Suzuki et al., 2017; Wang et al., 2018). CS expo-
sure alone significantly increased cellular infiltration foci in 
mouse lung parenchyma compared with controls. However, 
we also show that low-dose azithromycin significantly re-
duced the number of these foci, which could contribute to the 
reduction in emphysematous changes seen in CS + Azi mice, 
and reiterate the anti-inflammatory effects of this macrolide. 
Further studies are needed to elucidate the mechanisms un-
derlying the immunomodulatory activity of azithromycin in 
emphysema and COPD.
This study demonstrates that interventional treatment 
with low-dose azithromycin may attenuate emphysematous 
changes caused by chronic CS exposure in mice. Furthermore, 
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these changes were detectable using in vivo imaging tech-
niques, which correlated with histological analyses. To our 
knowledge, this is the first study to treat mice with low-dose 
azithromycin following the development of a CS-induced in-
flammatory lung environment; representative of administer-
ing treatment to smokers who have sought medical advice as 
their lungs begin to deteriorate.
Limitations of this study include a lack of mechanistic 
data, resulting from insufficient cell numbers in BAL. Future 
studies that more extensively investigate mucus hypersecre-
tion (MUC5AC and MUC5B in the BAL), leukocyte subsets, 
neutrophil activation status, and soluble mediator production, 
focusing on some of the mediators that might be interesting 
in human COPD development (e.g., neutrophil elastase/other 
proteases) are warranted. Also worth investigating is the 
mechanism through which azithromycin could modulate em-
physema development through alteration of the respiratory 
tract (or gut) microbiome.
Although further work is required, the findings of this 
study suggest that intervention with long-term, low-dose azi-
thromycin treatment may offer therapeutic benefits to current 
smokers (particularly those who are attempting to quit) and 
patients with early pulmonary emphysema.
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